Ricky W Johnstone Selected Research

Histone Deacetylase Inhibitors

1/2022	The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression.
1/2022	Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AML.
11/2021	A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer.
1/2021	Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma.
1/2017	HDAC Inhibitor Panobinostat Engages Host Innate Immune Defenses to Promote the Tumoricidal Effects of Trastuzumab in HER2+ Tumors.
11/2016	How do tumor cells respond to HDAC inhibition?
7/2016	Long term, continuous exposure to panobinostat induces terminal differentiation and long term survival in the TH-MYCN neuroblastoma mouse model.
11/2015	Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies.
4/2015	Manipulation of B-cell responses with histone deacetylase inhibitors.
1/2015	Combining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t(8;21) acute myeloid leukemia.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ricky W Johnstone Research Topics

Disease

99	Neoplasms (Cancer) 07/2022 - 01/2002
20	Lymphoma (Lymphomas) 01/2021 - 03/2008
19	Hematologic Neoplasms (Hematological Malignancy) 01/2022 - 05/2008
15	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2022 - 10/2012
13	Leukemia 01/2022 - 07/2011
10	Carcinogenesis 12/2018 - 01/2002
9	B-Cell Lymphoma (Lymphoma, B Cell) 01/2019 - 05/2008
5	Breast Neoplasms (Breast Cancer) 10/2021 - 08/2008
4	Melanoma (Melanoma, Malignant) 10/2021 - 04/2012
4	Multiple Myeloma 12/2018 - 07/2012
4	Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous) 10/2012 - 05/2008
3	Autoimmune Diseases (Autoimmune Disease) 01/2022 - 04/2012
3	Infections 05/2014 - 10/2008
2	Immune System Diseases (Immune Disorders) 07/2022 - 09/2014
2	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2022 - 01/2019
2	Starvation 01/2022 - 05/2002
2	Neuroblastoma 01/2021 - 07/2016
2	Thrombocytopenia (Thrombopenia) 12/2020 - 03/2011
2	Disease Progression 01/2016 - 11/2013
2	Hypoxia (Hypoxemia) 04/2014 - 07/2012
2	Ovarian Neoplasms (Ovarian Cancer) 12/2013 - 08/2011
2	Virus Diseases (Viral Diseases) 02/2012 - 04/2010
1	Pancreatic Neoplasms (Pancreatic Cancer) 11/2021
1	Retinoblastoma (Glioblastoma, Retinal) 10/2021
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2021

Drug/Important Bio-Agent (IBA)

37	Histone Deacetylase InhibitorsIBA 01/2022 - 04/2002
26	Proteins (Proteins, Gene)FDA Link 01/2022 - 05/2002
15	PanobinostatIBA 01/2022 - 07/2008
9	CytokinesIBA 01/2022 - 04/2010
9	Pharmaceutical PreparationsIBA 01/2017 - 01/2002
9	Vorinostat FDA Link 11/2015 - 07/2004
8	Histone Deacetylases (Histone Deacetylase)IBA 01/2022 - 04/2013
7	ChromatinIBA 01/2022 - 01/2009
7	EnzymesIBA 01/2022 - 06/2009
7	Chimeric Antigen ReceptorsIBA 11/2021 - 06/2016
7	InterferonsIBA 09/2019 - 10/2008
7	Biological ProductsIBA 11/2016 - 05/2008
6	AntibodiesIBA 01/2017 - 10/2008
5	Histones (Histone)IBA 01/2021 - 01/2009
5	romidepsin (FK228)FDA Link 01/2017 - 05/2008
5	DNA (Deoxyribonucleic Acid)IBA 12/2015 - 06/2009
5	Monoclonal AntibodiesIBA 08/2014 - 08/2008
4	venetoclaxIBA 01/2021 - 12/2018
4	PerforinIBA 01/2019 - 02/2009
4	Therapeutic UsesIBA 01/2017 - 03/2011
4	Mechanistic Target of Rapamycin Complex 1IBA 01/2016 - 01/2013
3	Immune Checkpoint InhibitorsIBA 01/2022 - 12/2015
3	Antineoplastic Agents (Antineoplastics)IBA 01/2022 - 03/2008
3	VaccinesIBA 11/2021 - 10/2012
3	Phosphotransferases (Kinase)IBA 10/2021 - 04/2013
3	Biomarkers (Surrogate Marker)IBA 01/2021 - 07/2003
3	birinapantIBA 01/2019 - 01/2016
3	AntigensIBA 01/2018 - 06/2016
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2018 - 10/2008
3	CX 5461IBA 01/2017 - 07/2012
3	Ribosomal DNA (rDNA)IBA 01/2016 - 07/2012
3	CaspasesIBA 01/2016 - 05/2002
3	TOR Serine-Threonine KinasesIBA 08/2014 - 12/2013
3	ABT-737IBA 11/2013 - 02/2009
3	Death Domain ReceptorsIBA 07/2009 - 08/2008
2	Cyclin-Dependent Kinases (cdk Proteins)IBA 01/2022 - 10/2021
2	Drug CombinationsIBA 01/2022 - 01/2021
2	CBLC137IBA 01/2022 - 01/2021
2	RNA (Ribonucleic Acid)IBA 10/2021 - 07/2016
2	Cytostatic AgentsIBA 10/2021 - 01/2017
2	Azacitidine (5 Azacytidine)FDA Link 12/2020 - 10/2013
2	Arsenic Trioxide (Trisenox)FDA Link 11/2020 - 01/2015
2	AutoantigensIBA 05/2017 - 03/2017
2	RNA Polymerase I (Polymerase I, RNA)IBA 01/2017 - 07/2012
2	Everolimus FDA Link 01/2016 - 01/2013
2	Oncogene Proteins (Oncogene Protein)IBA 07/2014 - 12/2012
2	Glucose (Dextrose)FDA LinkGeneric 04/2014 - 08/2011
2	Galactosylceramides (Galactocerebrosides)IBA 12/2013 - 10/2012
2	2- amino- 8- (4- (2- hydroxyethoxy)cyclohexyl)- 6- (6- methoxypyridin- 3- yl)- 4- methylpyrido(2,3- d)pyrimidin- 7(8H)- oneIBA 12/2013 - 08/2011
2	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 12/2013 - 08/2011
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 12/2013 - 08/2011
2	mirdametinibIBA 12/2013 - 08/2011
2	LigandsIBA 10/2012 - 10/2008
2	TNF-Related Apoptosis-Inducing LigandIBA 02/2012 - 10/2008
1	pyrimidineIBA 01/2022
1	Interferon Type IIBA 01/2022
1	Dihydroorotate DehydrogenaseIBA 01/2022
1	Bispecific AntibodiesIBA 01/2022
1	Carrier Proteins (Binding Protein)IBA 01/2022
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 10/2021
1	Immunologic Adjuvants (Immunologic Adjuvant)IBA 10/2021
1	Hormones (Hormone)IBA 10/2021
1	Immunomodulating AgentsIBA 10/2021
1	fms-Like Tyrosine Kinase 3IBA 01/2021
1	Polysaccharides (Glycans)IBA 01/2021
1	Nucleosomes (Nucleosome)IBA 01/2021
1	Serine (L-Serine)FDA Link 01/2021
1	SugarsIBA 01/2021
1	Lysine AcetyltransferasesIBA 01/2021

Therapy/Procedure

41	Therapeutics 07/2022 - 01/2002
12	Immunotherapy 01/2022 - 12/2007
6	Drug Therapy (Chemotherapy) 01/2022 - 01/2002
3	Radiotherapy 08/2014 - 07/2012
2	Transplantation 01/2021 - 07/2012
1	Combined Modality Therapy 01/2021